Nanocarriers as an Emerging Platform for Cancer Therapy
暂无分享,去创建一个
J. Karp | R. Langer | D. Peer | Seungpyo Hong | O. Farokhzad | R. Margalit | V. Dragowska | M. Bally | E. Ramsay | M. Anantha | K. Gelmon | Jehan Alnajim | D. Waterhouse | Karen Fang | Gwyn Bebb | Richard J. Klasa | Nancy Dos Santos | Ellen K Wasan | Catherine Tucker | Juliana Yeung | Lincoln Edwards | Yanping Hu | Corrina Warburton | Sheela Abraham | Gigi Chui
[1] J. Kreuter,et al. Improved delivery of methoxsalen. , 1979, Journal of pharmaceutical sciences.
[2] P Couvreur,et al. Adsorption of antineoplastic drugs to polyalkylcyanoacrylate nanoparticles and their release in calf serum. , 1979, Journal of pharmaceutical sciences.
[3] P Couvreur,et al. Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles. , 1980, Journal of pharmaceutical sciences.
[4] C. Milstein,et al. Attempted targeting of a monoclonal antibody in a human tumour xenograft system. , 1981, European journal of cancer & clinical oncology.
[5] P. Couvreur,et al. Toxicity of polyalkylcyanoacrylate nanoparticles II: Doxorubicin-loaded nanoparticles. , 1982, Journal of pharmaceutical sciences.
[6] M. El-Samaligy,et al. Reconstituted collagen nanoparticles, a novel drug carrier delivery system , 1983, The Journal of pharmacy and pharmacology.
[7] I. Thesleff,et al. Distribution of the transferrin receptor in normal human fibroblasts and fibrosarcoma cells , 1983, International journal of cancer.
[8] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[9] D. Scheinberg,et al. Monoclonal antibody therapy of cancer. , 1990, Cancer chemotherapy and biological response modifiers.
[10] A. Gabizon,et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[11] A. Antony,et al. The biological chemistry of folate receptors. , 1992, Blood.
[12] P. Trail,et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. , 1993, Science.
[13] W. Ouwehand,et al. Human Antibody Fragments Specific for Human Blood Group Antigens from a Phage Display Library , 1993, Bio/Technology.
[14] Y. Barenholz,et al. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. , 1993, Biochimica et biophysica acta.
[15] A. Frankel. Immunotoxin therapy of cancer. , 1993, Oncology.
[16] T. Allen. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. , 1994, Trends in pharmacological sciences.
[17] E. Ruoslahti. Cell adhesion and tumor metastasis. , 1994, Princess Takamatsu symposia.
[18] R K Jain,et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.
[19] A. Kabanov,et al. Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity. , 1996, British Journal of Cancer.
[20] D. Doering,et al. Quantitative analyses of epidermal growth factor receptors, HER‐2/neu oncoprotein and cathepsin D in nonmalignant and malignant uteri , 1996, Cancer.
[21] R. Langer,et al. Nanotechnology for biomaterials engineering: structural characterization of amphiphilic polymeric nanoparticles by 1H NMR spectroscopy. , 1997, Biomaterials.
[22] M. Uhlén,et al. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. , 1997, Nature biotechnology.
[23] R. Jain,et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[24] E. Ruoslahti,et al. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.
[25] A. Aurengo,et al. Differential transferrin receptor density in human colorectal cancer: A potential probe for diagnosis and therapy. , 1998, International journal of oncology.
[26] T M Allen,et al. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. , 1998, Cancer research.
[27] K. Gelmon,et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. , 1999, Journal of Clinical Oncology.
[28] Zhiwei Hu,et al. Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[29] J. Baselga,et al. Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. , 1999, Drugs of today.
[30] S. Groshen,et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] Louis M Weiner,et al. New approaches to antibody therapy , 2000, Oncogene.
[32] B. Sullenger,et al. Developing aptamers into therapeutics. , 2000, The Journal of clinical investigation.
[33] E. W. Meijer,et al. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[34] D. Tzemach,et al. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[35] A. Gabizon. Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy , 2001, Cancer investigation.
[36] A. Gabizon. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[37] F. Szoka,et al. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. , 2001, Cancer research.
[38] F. Garbagnati,et al. Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI‐007) , 2001, Cancer.
[39] G. Adams,et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. , 2001, Cancer research.
[40] T. Okano,et al. Development of the polymer micelle carrier system for doxorubicin. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[41] P. Carter,et al. Improving the efficacy of antibody-based cancer therapies , 2001, Nature Reviews Cancer.
[42] T. Tsuruo,et al. Possibility of the reversal of multidrug resistance and the avoidance of side effects by liposomes modified with MRK-16, a monoclonal antibody to P-glycoprotein. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[43] T. Allen. Ligand-targeted therapeutics in anticancer therapy , 2002, Nature Reviews Cancer.
[44] M. Gottesman,et al. Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.
[45] K. Maruyama,et al. Intracellular targeting therapy of cisplatin‐encapsulated transferrin‐polyethylene glycol liposome on peritoneal dissemination of gastric cancer , 2002, International journal of cancer.
[46] Ulrik B Nielsen,et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[47] C. Halin,et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature , 2002, Nature Biotechnology.
[48] P. Couvreur,et al. Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.
[49] J. Proost,et al. Targeting of RGD‐modified proteins to tumor vasculature: A pharmacokinetic and cellular distribution study , 2002, International journal of cancer.
[50] Theresa M Allen,et al. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. , 2002, Cancer research.
[51] Robert Langer,et al. Advancing the field of drug delivery: taking aim at cancer. , 2003, Cancer cell.
[52] Robert Langer,et al. Small-scale systems for in vivo drug delivery , 2003, Nature Biotechnology.
[53] T. Allen,et al. Ligand-targeted liposomal anticancer drugs. , 2003, Progress in lipid research.
[54] Michele Follen,et al. Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles. , 2003, Cancer research.
[55] R. Stafford,et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[56] J. Levron. Chapter-28 Blastocyst Transfer: One Step Further in the Quest for the Magic Bullet , 2003 .
[57] B. Stewart,et al. World Cancer Report , 2003 .
[58] M. Alonso,et al. Chitosan and Chitosan/Ethylene Oxide-Propylene Oxide Block Copolymer Nanoparticles as Novel Carriers for Proteins and Vaccines , 1997, Pharmaceutical Research.
[59] T. Wagner,et al. Fusion protein from RGD peptide and Fc fragment of mouse immunoglobulin G inhibits angiogenesis in tumor , 2004, Cancer Gene Therapy.
[60] Serge Muyldermans,et al. Efficient cancer therapy with a nanobody-based conjugate. , 2004, Cancer research.
[61] J. Davies,et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470 , 2004, Nature Medicine.
[62] Matthew R Cooperberg,et al. Mapping Tumor Epitope Space by Direct Selection of Single-Chain Fv Antibody Libraries on Prostate Cancer Cells , 2004, Cancer Research.
[63] J. Marks. Selection of internalizing antibodies for drug delivery. , 2004, Methods in molecular biology.
[64] H. Ueno,et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin , 2004, British Journal of Cancer.
[65] M. Alonso. Nanomedicines for overcoming biological barriers. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[66] H. Yanagie,et al. Liposomes Bearing Polyethyleneglycol-Coupled Transferrin with Intracellular Targeting Property to the Solid Tumors In Vivo , 2001, Pharmaceutical Research.
[67] D. Peer,et al. Loading mitomycin C inside long circulating hyaluronan targeted nano‐liposomes increases its antitumor activity in three mice tumor models , 2004, International journal of cancer.
[68] D. Kerr,et al. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer , 2004, British Journal of Cancer.
[69] J. Hornaday,et al. Cancer Facts & Figures 2004 , 2004 .
[70] D. Peer,et al. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. , 2004, Neoplasia.
[71] You Han Bae,et al. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[72] Samuel A Wickline,et al. Targeted contrast agents for magnetic resonance imaging and ultrasound. , 2005, Current opinion in biotechnology.
[73] J. West,et al. Metal Nanoshells , 2005, Annals of Biomedical Engineering.
[74] V. Torchilin. Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.
[75] R. Nicholson,et al. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. , 2005, Endocrine-related cancer.
[76] S. Jeffers,et al. Pegylated liposomal doxorubicin ( doxil ) : Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg / m 2 , 2005 .
[77] Napoleone Ferrara,et al. VEGF as a Therapeutic Target in Cancer , 2005, Oncology.
[78] J. Fréchet,et al. Dendrimers and dendritic polymers in drug delivery. , 2005, Drug discovery today.
[79] Thommey P. Thomas,et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. , 2005, Cancer research.
[80] M. Ferrari. Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.
[81] W. Stemmer,et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains , 2005, Nature Biotechnology.
[82] Shiladitya Sengupta,et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system , 2005, Nature.
[83] J. West,et al. Immunotargeted nanoshells for integrated cancer imaging and therapy. , 2005, Nano letters.
[84] Hui Zhang,et al. Gold nanocages: bioconjugation and their potential use as optical imaging contrast agents. , 2005, Nano letters.
[85] H. Ueno,et al. Phase I study of NK105, a paclitaxel-incorporating micellar nanoparticle, in patients with advanced cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] H. Shmeeda,et al. Pros and Cons of the Liposome Platform in Cancer Drug Targeting , 2006, Journal of liposome research.
[87] Frank Bates,et al. Shrinkage of a rapidly growing tumor by drug-loaded polymersomes: pH-triggered release through copolymer degradation. , 2006, Molecular pharmaceutics.
[88] Sevim Z. Erhan,et al. A New Polymer–Lipid Hybrid Nanoparticle System Increases Cytotoxicity of Doxorubicin Against Multidrug-Resistant Human Breast Cancer Cells , 2006, Pharmaceutical Research.
[89] P. Couvreur,et al. Nanotechnology: Intelligent Design to Treat Complex Disease , 2006, Pharmaceutical Research.
[90] Ruth Duncan,et al. Polymer conjugates as anticancer nanomedicines , 2006, Nature Reviews Cancer.
[91] Joseph M. McLellan,et al. Facile synthesis of gold-silver nanocages with controllable pores on the surface. , 2006, Journal of the American Chemical Society.
[92] R. Kontermann,et al. Immunoliposomes for cancer therapy. , 2006, Current opinion in molecular therapeutics.
[93] Roey J. Amir,et al. Polymer therapeutics : polymers as drugs, conjugates and gene delivery systems , 2006 .
[94] S Moein Moghimi,et al. Recent developments in polymeric nanoparticle engineering and their applications in experimental and clinical oncology. , 2006, Anti-cancer agents in medicinal chemistry.
[95] V. Torchilin,et al. Micellar Nanocarriers: Pharmaceutical Perspectives , 2006, Pharmaceutical Research.
[96] J. Richie,et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[97] R. Langer,et al. Nanomedicine: developing smarter therapeutic and diagnostic modalities. , 2006, Advanced drug delivery reviews.
[98] J. Benoit,et al. A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats , 2006, Molecular Cancer Therapeutics.
[99] D. Peer,et al. Fluoxetine and reversal of multidrug resistance. , 2006, Cancer letters.
[100] R. Guo,et al. Synthesis of alginic acid-poly[2-(diethylamino)ethyl methacrylate] monodispersed nanoparticles by a polymer-monomer pair reaction system. , 2007, Biomacromolecules.
[101] Seungpyo Hong,et al. The Binding Avidity of a Nanoparticle-based Multivalent Targeted Drug Delivery Platform , 2022 .
[102] J. Lieberman,et al. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1 , 2007, Proceedings of the National Academy of Sciences.
[103] Sung-Bae Kim,et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer , 2008, Breast Cancer Research and Treatment.
[104] A. Alavi,et al. Opportunities and Challenges , 1998, In Vitro Diagnostic Industry in China.
[105] F. Dentali,et al. Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura , 2007, Annals of Internal Medicine.
[106] G. Scambia,et al. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.